Alzheimer's Disease Therapeutics Market size to increase by USD 5.41 Billion between 2023 to 2028, Market Segmentation by Distribution Channel, Drug Class, Geography , Technavio

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The global alzheimer's disease therapeutics market size is estimated to grow by USD 5.41 billion from 2024 to 2028, according to Technavio. The market is estimated to grow at a CAGR of 10.03% during the forecast period. The report provides a comprehensive forecast of key segments below- 

Segmentation Overview

• 1.1 Hospital pharmacy
• 1.2 Retail pharmacy
• 1.3 E-commerce pharmacy

• 2.1 Cholinesterase inhibitors
• 2.2 N-methyl-D-aspartate receptor antagonist
• 2.3 Others

• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

Get a glance at the market contribution of rest of the segments - Download a FREE Sample Report in minutes!

1.1 Fastest growing segment:

The hospital pharmacy segment of the Alzheimer's disease therapeutics market is experiencing significant growth due to the large-scale demand for these drugs in hospitals. This trend is driven by several factors, including increasing government investments in healthcare infrastructure in countries like India and China, the expansion of hospital facilities in developing nations, and the rising number of Alzheimer's disease cases worldwide. As a result, hospitals are becoming major distribution channels for Alzheimer's disease therapeutics. These factors collectively are expected to boost the growth of the hospital segment of the Alzheimer's disease therapeutics market during the forecast period.

Analyst Review

The Alzheimer's disease therapeutics market encompasses innovative treatments for neurodegenerative diseases, primarily Alzheimer's and dementias. Two major categories include Amyloid beta inhibitors and biological therapies. These treatments aim to slow down the progression of these conditions by targeting the buildup of beta-amyloid plaques and tau tangles in the brain. Both men and women are affected, with women making up two-thirds of the estimated 5.8 million Americans living with Alzheimer's disease. Life expectancy plays a significant role, as the majority of Medicare beneficiaries, who are aged 65 and above, are at increased risk. The prescription rate for these therapies is growing as more clinics and hospitals integrate cognitive assessment systems into their routine patient care. Memory impairment, thinking, behavioral skills, and social skills are common symptoms, affecting everyday tasks and quality of life.

Market Overview

Alzheimer's disease, a leading cause of dementia and neurodegenerative diseases, affects memory impairment, thinking, and social skills in older adults. The Alzheimer's disease therapeutics market is witnessing significant advancements in treatment with the development of various drug classes, including cholinesterase inhibitors (Aricept, Exelon, Razadyne) and Amyloid beta inhibitors (Crenezumab). Biological therapies, such as Tau antibody, are also under investigation. Cognitive assessment systems aid in diagnosis, while distribution channels, including hospitals, hospital pharmacies, online pharmacies, and e-commerce platforms, facilitate access to these essential medications. With an increasing number of diagnosed patients, particularly among older adults, life expectancy, and Medicare beneficiaries, the prescription rate for Alzheimer's disease therapeutics continues to rise. The use of drug discovery techniques and technological advancements, such as smartphones and the Internet, are revolutionizing the way these therapies are administered and monitored. Despite these advancements, Alzheimer's disease remains a significant cause of disability and deaths, with a disproportionate impact on Men and Women. The pipeline drugs offer hope for future treatments, aiming to slow down the progression of the disease and improve the quality of life for those affected.

To understand more about this market- Download a FREE Sample Report in minutes!

Key Topics Covered:

 1 Executive Summary
 2 Market Landscape
 3 Market Sizing
 4 Historic Market Size
 5 Five Forces Analysis
 6 Market Segmentation
 7 Customer Landscape
 8 Geographic Landscape
 9 Drivers, Challenges, and Trends
10 Venodr Landscape
11 Vendor Analysis

• AB Science SA
• AbbVie Inc.
• AgeneBio Inc.
• Biogen Inc.
• Cipla Ltd.
• Curasia Medilab
• Denali Therapeutics Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Grifols SA
• H Lundbeck AS
• Johnson and Johnson
• Lifecare Neuro Products Ltd.
• Lupin Ltd.
• Novartis AG
• Pfizer Inc.
• Psycogen Captab
• Solco Healthcare
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.

12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-disease-therapeutics-market-size-to-increase-by-usd-5-41-billion-between-2023-to-2028--market-segmentation-by-distribution-channel-drug-class-geography--technavio-302352012.html

SOURCE Technavio